Go To Global Site
Welcome to UCB in the United States

Oct

12

Curiosity and Engagement are Key, Not Gender: Women & Diversity in Science with Yuan Wang

As a Senior Principal Data Scientist, Yuan Wang, PhD, uses her strength for uniting different people in her field to drive innovation at UCB, and encourages her team to value the importance of diversity in collaboration. Read her story. 

Oct

08

UCB Researchers Virtually Advocate for Innovation

Last week, UCB researchers from across the country gathered virtually for the PhRMA Researcher Fly-In where more than 70 industry researchers engaged with Members of Congress. Read their stories. 

Oct

07

Expanded Relationship with Aetion Advances UCB’s Digital Business Transformation

UCB and Aetion announced a new agreement to advance UCB’s use of real-world evidence (RWE) using rapid and robust analytics. 

Sep

28

Every Scientist’s Dream: Women and Diversity in Science with Nikita Dalal

At UCB, we know we need diverse perspectives and experiences to do our best work. Passionate scientists like Nikita, who exemplify our vision to embrace new knowledge and to work to discover meaningful solutions for patients, are a driving force for innovation at UCB. Stay tuned over the next few weeks to read stories from UCB women researchers who are pushing the boundaries of science. 

1200x675.UCB_LOGO_TAG_C_RGB_600.jpg

Sep

22

UCB Achieves Important Regulatory Milestone for Bimekizumab

  • The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis
  • This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara® (ustekinumab) and Humira® (adalimumab) in achieving skin clearance at week 16
1200x675.UCB_LOGO_TAG_C_RGB_600.jpg

Sep

14

Final Phase II Results for UCB’s Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances

•    Phase II data demonstrated a favorable safety profile across all reported dose groups and clinically meaningful platelet count increases with meaningful decreases in IgG concentration 

Sep

10

Improving Diversity in Dermatology

UCB is participating in the Skin of Color Update (“SOCU”) Dermatology Conference, a forum for medical specialists to discuss trending evidence-based research and best practices for skin of color in dermatology. This year’s SOCU comes at an important time for the healthcare community and serves as an opportunity to have conversations and problem solve around inequities in dermatological care. Read more from Rhonda Peebles, Head of U.S. Dermatology, as she shares her thoughts on racial inequities in dermatology and the steps UCB is taking to move the equity needle forward. 

Sep

10

PharmD Fellows Experience It All with UCB’s Fellowship Program

UCB is committed to investing in the future generation of leaders. Established in 2017, the UCB Global Regulatory Affairs (GRA) PharmD Fellowship Program, a collaboration with the Industry Pharmacists Organization (IPhO), was designed to provide PharmD graduates with the opportunity to learn and experience all aspects of regulatory affairs under the mentorship of experienced preceptors.

Sep

03

Our Commitment to Employee Growth and Development: UCB Speaks

At UCB, we understand our ability to provide impactful solutions patients value begins with our commitment to our employees. As a company, we pride ourselves in the internal resources and programs available to all employees to encourage professional and personal development. We are pleased to introduce a new series here highlighting UCB as an employer. Today we’re shining a spotlight on our internal organization sponsored by Toastmasters International: UCB Speaks.

Aug

31

Press Release: Phase 3 data on VIMPAT® (lacosamide) CV in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry

  • Study met primary and secondary endpoints of significantly lowering the risk of developing a second primary generalized tonic-clonic seizure (PGTCS) during a 24-week treatment and a significantly higher rate of freedom from PGTCS during the treatment period compared with placebo